(Reuters) – Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in high-risk hospitalized adults tested positive for COVID-19.
The company expects to report topline data in the first quarter of 2021.
Fulcrum said it had exclusively in-licensed losmapimod from GlaxoSmithKline PLC last year.
(Reporting By Mrinalika Roy in Bengaluru, Editing by Sherry Jacob-Phillips)
